A Phase 2 Trial to Investigate the Efficacy, Safety and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)

This Phase 2 clinical trial titled "A Phase 2 Trial to Investigate the Efficacy, Safety and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)" focuses on evaluating efgartigimod PH20 administered subcutaneously (SC) in adult patients diagnosed with CIDP, with the objective of assessing efficacy, safety and tolerability. As a Phase 2 study, ADHERE is positioned to gather preliminary controlled data on the therapeutic activity of efgartigimod PH20 in this patient population as well as characterize its safety profile and tolerability when delivered by the subcutaneous route.

The trial title and registration context indicate that the study is oriented toward adults with CIDP and is intended to produce evidence informing whether efgartigimod PH20 merits further clinical development for this indication. The registry context (ClinicalTrials.gov) implies that study record managers and investigators are following standard registration practices for clinical research, ensuring that core protocol and outcome information are available in a centralized public record. The ADHERE trial's inclusion of efficacy, safety, and tolerability in its primary aims suggests a balanced assessment that will consider both clinical benefit and potential risks or adverse effects associated with treatment.

Efgartigimod PH20 SC is being evaluated specifically via subcutaneous administration, which is notable for its potential implications on treatment delivery and patient experience. Subcutaneous formulations can offer advantages in terms of outpatient administration and patient convenience; thus, assessment of tolerability and local reactogenicity are likely important components of this study's safety evaluation. The Phase 2 setting allows the trial to refine dosing, better define the therapeutic window, and identify signals of efficacy that will inform the design of subsequent larger trials.